A detailed history of Susquehanna International Group, LLP transactions in Meira G Tx Holdings PLC stock. As of the latest transaction made, Susquehanna International Group, LLP holds 12,724 shares of MGTX stock, worth $79,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,724
Holding current value
$79,906
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.88 - $5.23 $49,369 - $66,546
12,724 New
12,724 $53,000
Q4 2023

Feb 14, 2024

BUY
$3.6 - $7.15 $53,805 - $106,863
14,946 New
14,946 $104,000
Q2 2023

Aug 11, 2023

SELL
$5.19 - $8.07 $20,967 - $32,602
-4,040 Reduced 23.61%
13,072 $87,000
Q1 2023

May 16, 2023

SELL
$5.04 - $8.6 $117,038 - $199,709
-23,222 Reduced 57.57%
17,112 $88,000
Q4 2022

Feb 14, 2023

SELL
$5.8 - $8.98 $1,183 - $1,831
-204 Reduced 0.5%
40,334 $262,000
Q3 2022

Nov 14, 2022

BUY
$7.55 - $11.25 $118,829 - $177,063
15,739 Added 63.47%
40,538 $341,000
Q2 2022

Aug 15, 2022

BUY
$6.8 - $14.23 $107,406 - $224,762
15,795 Added 175.42%
24,799 $188,000
Q4 2021

Feb 14, 2022

BUY
$12.78 - $23.74 $115,071 - $213,754
9,004 New
9,004 $214,000
Q2 2021

Aug 11, 2021

SELL
$12.85 - $16.2 $293,840 - $370,445
-22,867 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$13.84 - $17.8 $9,937 - $12,780
718 Added 3.24%
22,867 $330,000
Q4 2020

Feb 16, 2021

BUY
$12.4 - $17.6 $274,647 - $389,822
22,149 New
22,149 $335,000
Q3 2020

Nov 16, 2020

SELL
$11.59 - $14.93 $118,577 - $152,748
-10,231 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$11.79 - $15.97 $120,623 - $163,389
10,231 New
10,231 $128,000
Q1 2020

May 15, 2020

SELL
$9.31 - $21.24 $133,384 - $304,305
-14,327 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$13.91 - $21.48 $199,288 - $307,743
14,327 New
14,327 $287,000

Others Institutions Holding MGTX

About MeiraGTx Holdings plc


  • Ticker MGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,010,700
  • Market Cap $283M
  • Description
  • MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...
More about MGTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.